TL13-12

N/A

Report date: 2022/12/08 17:49:11
NME

Base Information

Drug NameTL13-12
Drug Alias NameTL13-12
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionAnaplastic lymphoma kinase inhibitorsProteolysis
TargetsAnaplastic lymphoma kinase
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHarvard University
China Registration ClassN/A

Develop Information

Active CompaniesHarvard University
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A